Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment

NCT06416865 is registered in ClinicalTrials.gov with AJU Pharm Co., Ltd. as lead sponsor.

NCT NCT06416865
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06416865 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of AJU-C52 in Compared With C52R1M for Essential Hypertension Patients in Inappropriately Controlled on C52R1L Treatment
Lead sponsor
AJU Pharm Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 18, 2022
Completion date
February 19, 2025
Enrollment
193 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential hypertension